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ABSTRACT
Objective: The objective of the current work is to develop dissolution method for the formulation contains mix pellets of omeprazole delayed release 
(DR) and extended release.
Methods: The dissolution method design was based on the quality by design principles, the selection of dissolution media, apparatus and drug 
release specification was based on scientific understanding of drug release mechanism and stability of omeprazole. Design of experiments (DOE) 
employed to assess the huskiness of the dissolution test using pH, volume of media and concentration of surfactant as critical test parameters.
Results: Omeprazole DDR formulation shows more than 85% cumulative drug release at 105 minutes with the % RSD less than 5 among six units. 
Based on p values (<0.1) of Shapiro-Wilk test for normality, Response-1 and 2 are statistically analysed with ANOVA statistics. The ANOVA analysis 
shows significant effect of ‘volume’ and ‘pH’ of dissolution media (p<0.05) on Quality Target Test Profile.
Conclusion: The outcome of DOE assessed with 95% confidence interval ANOVA statistics, which reveals that the dissolution test is rugged and can 
be used for routine quality control test of omeprazole dual DR formulation.
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INTRODUCTION
Over the last few decades, use of the dissolution test for quality 
check purpose has remarkably increased in the pharmaceutical 
industries [1-3]. Dissolution test is a vital tool to assess the formulation 
performance in vivo and also a quality control test for monitoring 
quality of formulation product. Dissolution profile comparison is 
most important to waive in vivo the bioequivalence study, particularly 
during scale up and post-approval changes to the product. The in vitro 
dissolution testing plays a major role to get approval from different 
regulatory agencies [3,4].
Opting dissolution test, next vital step is to select proper dissolution 
media considering factors like, complexity of formulation 
(i.e., modified release, extended release [ER], immediate release, 
sustain release, etc., molarity and pH of dissolution media require to 
ensure dissolution release, solubility of active and in-actives in the 
media, etc. All these factors have greater influence on drug product 
dissolution and so, evaluations of these parameters are very important 
for contemporary dissolution development [5-7]. Dickinson et al. 
demonstrate significance of quality by design (QbD) for clinical 
relevance of dissolution testing [8]. QbD is a systematic, scientific, 
risk-based, holistic and proactive approach to pharmaceutical 
development that begins with predefined objectives and emphases 
product and process understanding and process control. This 
approach uses statistical design of experiments (DOE) to develop 
a rugged method with “design space.” The design space defines the 
experimental region in which changes to method parameters will not 
significantly affect the quality and results of the method [9].
In the present work, the objective was to develop an in vitro dissolution 
test using QbD approach for newly devised omeprazole dual delayed-
release (DDR) formulation [10]. The formulation was designed for 
patients suffering from gastroesophageal reflux disease. Omeprazole 
DDR is a mixture of DR (DR; enteric coating) and ER (ER; controlled 
release) pellets. Thus, it has sustained action for long duration [11]. 
Since, omeprazole is an acid labile drug and is stable at around 
pH - 10 [11,12], the purpose was to build an in vitro dissolution test 
which discriminate the release of DR and ER part of omeprazole DDR 
formulation, using dissolution media similar to in vivo physiological 
condition in a short dissolution run time.
EXPERIMENTALS
Chemicals
Test samples of omeprazole pellets and all chemicals provided by 
Dr. Reddy’s Laboratories (Hyderabad, India). Extra pure grades of 
monobasic sodium phosphate anhydrous (Merck, Mumbai), sodium 
hydroxide (Merck, Mumbai), Sodium dodecyl sulfate or sodium lauryl 
sulfate (SLS) (Merck, Mumbai), hydrochloric acid (35%) (Merck, 
Mumbai), triethylamine (Qualigens, Mumbai) and high pressure liquid 
chromatography (HPLC) grades of methanol and acetonitrile (Merck, 
Mumbai) used for experimentation. Millipore 0.45 μm membrane 
filters, polypropylene syringe filter holder, were purchased from 
Millipore Corp. (Bedford, MA, USA).
Equipments
Dissolution (DISSO 2000-Labindia Analytical Instruments Pvt. 
Ltd, India) apparatus attached with autosampler used to perform 
dissolution tests. The HPLC (Agilent, USA) used consists of a 
quaternary solvent manager, a sample manager and a ultra violet-
visible multiple wavelength detector. The output signal monitored 
and processed using Empower 2 software (Waters Corporation; 
Milford, Massachusetts).
Brief about chromatographic conditions
The chromatographic column used was a thermo hypersil BDS, C-18, 
150 mm × 4.6 mm, 5 µm particle size column. After injecting 20 µL 
samples, elution was carried out using isocratic mode at a flow rate 
of 1.2 mL/minutes. The mobile phase used for elution was a mixture 
of pH 7.4 triethylamine buffer and methanol in the ratio 45:55 (v/v) 
respectively. The detection was monitored at a wavelength 305 nm.
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Standard preparation
A standard of 56 µg/mL was prepared using an accurately weighed 
amount of omeprazole standard in the dissolution media. The standard 
solution further stabilized using sodium hydroxide solution.
Brief about formulation
The omeprazole DDR formulation is a mixture of about 20 mg DR 
(≈33% of total formulation) and 40 mg ER (≈67 % of total formulation) 
pellets, where solubility and dispersion of DR part are pH dependent 
(which dissolved and release the drug between pH 5-7), while for ER 
part, it is pH independent. The DR part of the formulation is likely to 
facilitate loading dose of the drug while ER part is prone to maintain the 
concentration of the drug [9].
Dissolution media preparation; pH 7.0 buffer
Dissolution media containing 0.07 M monobasic sodium phosphate 
anhydrous, 0.09 M sodium hydroxide, 0.05 M hydrochloric acid and 
5 mM SLS, was prepared using purified water. The media deaeration 
performed as per general chapter <711> of US pharmacopeia.
Dissolution test
The dissolution studies were performed with USP apparatus-II, 
employing 900 mL of dissolution media at 37±0.5°C and a stirring rate 
of 75 RPM. After 15 and 105 minutes, a sample of about 10 mL was 
withdrawn from each vessel using cannula attached to autosampler and 
replacement of media was done immediately with nearly 10 mL of the 
fresh medium at 37±0.5°C. The samples were stabilized with sodium 
hydroxide solution and filtered through 0.45-μm nylon filters preceding 
assay by HPLC.
QbD
In QbD approaches, experimentation is carried out to determine 
the relationship between factors acting i.e., critical test parameters 
(CTP), on the process/test or a product, or both and the response 
or properties of the process/test or a product, i.e., critical quality 
attributes (CQAs). The information is then used to achieve the goal, 
i.e., quality target test profile (QTTP) of the process/test or a product. 
In the present work, QTTP for the dissolution test of omeprazole DDR 
was to discriminate the release of DR part and ER part and complete 
release formulation without potential degradation of omeprazole. 
The CTPs selected for DOE were volume of dissolution media, pH 
of the dissolution media and concentration of surfactant (SLS) 
(Table 1).
RESULTS AND DISCUSSION
Omeprazole is an acid liable drug and unstable at entire gastrointestinal 
(GI) tract pH range (1.2-7.5) [11,12]. Further; omeprazole DDR was 
formulated to commence hypothetical releases of drug from the 
upper jejunum (pH between 5.5 and 7) and provide greater than one 
release of omeprazole in vivo using DR and ER pellets [10,13]. Based 
on scientific understanding of omeprazole drug, formulation design 
and therapeutic target, the in vitro dissolution method development 
was started with QTTP as, dissolution method should be able to 
discriminate the DR and ER part and ensure more than 85% of 
cumulative drug release.
Initial method development trials were taken using the compendial 
dissolution medium [14] for omeprazole DDR capsules in which 
dissolution test was carried out for 8 hrs to ensure the complete 
release of formulation. However, due to instability of omeprazole in 
compendial media, the cumulative percentage drug dissolved after 
8 hrs was <50%. Mass balance of this result was confirmed with 
in-house developed related substance analytical method [15]. To 
prevent the drug degradation in dissolution media the approach of 
dissolution test with shorter dissolution run time was attempted 
with use of surface active agent in dissolution media, which 
facilitates the faster drug release from ER pellets, due to reduction 
in surface tension between pellets surface and dissolution media. At 
the end, dissolution media were finalized based on omeprazole DDR 
hypothetical release pattern in GI tract fluid, which contains salts 
and acids [10,13]. To maintain resemblance between in vitro and 
in vivo conditions a mixture of salts and acid were used to prepare 
dissolution media of pH 7.0, which is a combination of phosphate 
buffer and hydrochloric acid. SLS was selected as a surfactant for 
dissolution test and concentration was kept as 5 mM in dissolution 
media pH 7.0 buffers.
Optimization of dissolution method was done, using pH 7.0 buffer 
with 5 mM SLS as a dissolution medium, with USP-I and II apparatuses 
in which apparatus-II at RPM of 75 was finalized for dissolution test 
of developed formulation. Cumulative drug release from omeprazole 
DDR formulation was obtained more than 85%; at 105 minutes 
and % RSD among the six units were <5%. Discriminatory power 
of dissolution media was checked by dissolution of omeprazole 
DR and ER pallets separately with similar dissolution conditions 
(Fig. 1). Omeprazole DR pellets were completely released the drug 
within 15 minutes time while, at same time interval, drug releases 
from ER pellets were nil. The advanced dissolution test was shorter 
and ensures discrimination of DR and ER part without potential 
degradation of omeprazole in dissolution media (QTTP), which 
impels that drug release from omeprazole DDR capsule at the 
15 minutes intervals, is due to DR part only, whereas, 105 minutes 
drug release is the combination of DR and ER part (Fig. 1). Thus, the 
advanced method was suitable to check the quality of the product 
during routine QC testing.
DOE for ruggedness of the dissolution media
Omeprazole degrades at low pH [11,12], to ensure the complete 
drug release; pH was specified as one of the CTPs for DOE. Finalized 
dissolution media were a mixture of phosphate buffer and hydrochloric 
acid. Consequently, increase the volume of dissolution media will 
increase the concentration of hydronium ion, which may degrade the 
drug during the dissolution test. Hence, volume of the dissolution 
media was also selected as CTP. To reduce the test duration, surfactant 
was added in dissolution media, which increase the rate of drug release 
from the formulation; therefore, concentration of SLS was kept as one 
of the CTP (Table 1).
The drug release at 15 minutes due to DR part and at 105 minutes 
cumulative drug release for QTTP, hence, these two dissolution time 
points were comprised in DOE as CQAs (Table 1).
Table 1: CTP, CQA and QTTP for dissolution test
Omeprazole DDR dissolution
CTPs Range for DOE QTTP CQA
Law (−1) High (1)
Volume of dissolution media 800 ml 1000 ml % drug dissolved at 15 minutes 
should not be <30%
% drug dissolved 
at 15 minutes
pH of the dissolution media pH 6.8 pH 7.2
Concentration of surfactant (SLS) 4 mM 6 mM % drug dissolved at 105 minutes 
should not be <85%
% drug dissolved 
at 105 minutes
CTPs: Critical test parameters, QTTP: Quality target test profile, CQA: Critical quality attribute, DDR: Dual delayed release, SLS: Sodium lauryl sulfate
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To optimize the ruggedness of the dissolution media, two levels 
full factorial design with three center points has been generated 
(Table 2) using Design Expert V8 software (Waters Corporation; 
Milford, Massachusetts).
DOE result for response-1 and response-2
The Shapiro–Wilk test for normality was carried out for response-1 
(Fig. 2), where the p>0.10 when no terms (CMP) selected in the half-
normal plot. This indicates no statistically significant effect of any 
CMPs, within the selected range of DOE, on response-1. In addition, the 
unselected terms are not normally distributed. Similarly, Shapiro–Wilk 
normality test shows the p<0.1 with no terms selected (Fig. 3) in the 
half-normal plot for response-2. This indicates that, there are terms, 
which have statistically significant effects within the range selected 
for DOE, on this response and the unselected terms are normally 
distributed.
Based on above, ANOVA analysis with 95% confidence interval was 
performed only for the response-2. Volume and pH of the dissolution 
media were found the most significant CTPs (p<0.05) based on 
DOE (Table 3) results’ using ANOVA statics. The perturbation plot 
helps to compare the effect of all the factors (parameters for a 
method) at a specific point for the selected response. A steep slope 
or curvature in a factor shows that the response is sensitive to that 
factor, while relatively flat line shows insensitivity to change in that 
particular factor. If there are more than two factors, this plot could 
Fig. 1: Dissolution profile of delayed release, extended release and 
dual delayed release
Fig. 2: Half-normal plot for response-1
Fig. 3: Half-Normal plot for response-2
Fig. 4: Perturbation graph for response-1











pH of dissolution 
media
1 6 6 Block 1 Factorial 1 −1 1
2 11 0 Block 1 Center* 0 0 0
3 4 4 Block 1 Factorial 1 1 −1
4 10 0 Block 1 Center 0 0 0
5 2 2 Block 1 Factorial 1 −1 −1
6 8 8 Block 1 Factorial 1 1 1
7 5 5 Block 1 Factorial −1 −1 1
8 9 0 Block 1 Center 0 0 0
9 7 7 Block 1 Factorial −1 1 1
10 3 3 Block 1 Factorial −1 1 −1
11 1 1 Block 1 Factorial −1 −1 −1
*Center (0)=final dissolution media, SLS: Sodium lauryl sulfate
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be used to find those factors that most affect the response. The 
perturbation plot (Figs. 4 and 5) for response-1 and response-2, 
display the effect of all factors for chosen responses. The responses 
are plotted by changing only one factor over its range while 
holding all the other factors constant. The plots indicate no major 
effect of chosen parameters on response-1, while for response-2 
all the parameters are significantly affecting. The design space 
graph (Fig. 4) shows working range of selected (p<0.05) term for 
certain stipulation. Here, response-2 is the combine release of DR 
and ER; consequently, norm for design space was set between 88 
and 95%.
The design space, which is an imaginary area bounded by the extremes 
of the tested factors, of the method, can be appraised using, overlay 
graph (Figs. 6-8). In the graphs, the yellow region demonstrates proven 
acceptable working range of selected two parameters by keeping third 
parameters at the actual level. To get desired hypothetical in-vivo drug 
profile, in-vitro release of drug at 15 minutes should be >30% while 
the complete drug release at 105 minutes should be more than 85% 
(QTTP). Based on this, the criterion for design space was; 30% drug 
release at 15 minutes, while at 105 minutes, none of the DOE trials gave 
<87% cumulative release hence, it was set between 88 and 95% drug 
releases.
Table 3: ANOVA test results for response-1 and response-2
ANOVA statistics
Parameters 
selected for ANOVA 
analysis
Response-1 Response-2 Acceptance criteria 








A-SLS concentration NA NA 0.0259 Not significant p<0.05 for significant
B-volume of media NA NA 0.0062 Significant
C-pH of media NA NA <0.0001 significant p<0.05
Model NA NA <0.0001 Significant
Lake of fit NA NA 0.5207 Not significant
Curvature NA NA 0.5004 Not significant
*NA=Not applicable, #Test not performed as p value of Shapiro–Wilk normality test is >0.1, SLS: Sodium lauryl sulfate
Fig. 5: Perturbation graph for response-2
Fig. 6: Design space (yellow) for response-1 and response-2 with 
respect to pH of dissolution media and sodium lauryl sulfate 
concentration
Fig. 7: Design space (yellow) for response-1 and response-2 with 
respect to volume of dissolution media and sodium lauryl sulfate 
concentration
Fig. 8: Design space (yellow) for response-1 and response-2 with 
respect to pH and volume of dissolution media
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All the CTPs which affect the quality of product were well within design 
space. Hence, the dissolution test is suitable and robust to check the 
routine quality of omeprazole DDR capsule.
CONCLUSION
A simple, fast and robust method for dissolution test was developed for 
omeprazole DDR capsules based on QbD principles. The huskiness of 
the dissolution media assessed using DOE, by considering pH, volume 
of media and concentration of SLS as CTPs. The DOE results verified the 
developed dissolution test to be rugged and reproducible. The test can 
be used for routine quality control purpose of an ER formulation with 
acid labile drug.
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